20+
Years of experience in obesity clinical research
450
Clinical studies completed for diseases across the metabolic continuum
20
Contributions to 20 approved metabolic drugs and devices
Specialized expertise to accelerate obesity drug development
As the foremost clinical research provider specializing in the continuum of metabolic diseases, we have made significant contributions to obesity clinical research over the past two decades. ProSciento provides scientific and operational expertise in the design and management of all facets of obesity-related clinical research and development.
Patient and Site Engagement in Obesity Clinical Trials
Our data-driven recruitment strategies ensure enrollment of eligible patients at highly qualified sites for obesity trials, enhancing engagement and retention. ProSciento’s global network of clinical trial sites, supported with proven engagement solutions and advanced technologies, streamlines operations, boosts efficiency, and increases enrollment and retention, ensuring a positive experience.
Multifaceted Expertise Beyond Obesity
Working with a CRO focused on diseases across the metabolic continuum is critical. Obesity-associated pathophysiology extends beyond the metabolic and endocrine actions of white and brown adipocytes to the gastrointestinal tract and the brain’s role in maintaining energy homeostasis. Comorbidities are often associated with obesity, including type 2 diabetes, cardiovascular risk factors, metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH).
